Zim Laboratories reported Quarter 2 FY '27 total operating income of approximately Rs. 1,054 million, up 19% year-on-year. EBITDA was approximately Rs. 77 million at a 7.3% margin, while EU-GMP CAPA clarifications were being addressed.

4 source passages

Zim Laboratories Limited’s Earnings Conference Call for the 2nd Quarter and Half Year Ended September 30, 2026. For Quarter 2, Financial Year ‘27, the company reported total operating income of approximately Rs. 1,054 million, representing a year-on-year growth of 19% and sequential growth of 12%. EBITDA for the quarter stood at approximately Rs. 77 million, translating to an EBITDA margin of 7.3% compared to Rs. 34 million and a margin of 3.7% in quarter 1, 2027, an improvement of 365 basis points, driven by better topline performance. And within a few days, we will be responding with our set of documents on the clarifications that are being asked for. Open the document at this passage

Aug 7

Earnings call

Q1 2027 earnings call AI summary on its way

May 20

Earnings call

Q4 2026 earnings call AI summary on its way

Showing 1–3 of 3 documents